Protein Deimmunization

Immunogenicity—the ability of a substance that the body deems foreign to generate an immune response—can present challenges in the development of gene therapies and protein therapeutics.

Our proprietary protein deimmunization platform, Deimmunized by Design^®, uses artificial intelligence to reengineer proteins, with the goal of silencing their immunogenic properties while maintaining their therapeutic activity. Using this platform, we are working to determine the possibility of developing re-dosable gene therapies that could unlock new, high unmet need disease targets as well as potentially less immunogenic protein therapeutics.